These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34734039)

  • 1. Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a
    Li W; Ma Z; Fu X; Hao Z; Shang H; Shi J; Lei M; Xu M; Ning S; Hua X
    Ann Transl Med; 2021 Sep; 9(18):1487. PubMed ID: 34734039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.
    Zhang W; Shi J; Li R; Han Z; Li L; Li G; Yang B; Yin Q; Wang Y; Ke Y; Li Q
    Oncologist; 2020 May; 25(5):375-379. PubMed ID: 32045060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal leiomyosarcoma with
    Hong L; Wang YN; Zhang X; Zhou X; Fan S; Xu M; Zhang S; Jiang D
    J Gastrointest Oncol; 2022 Jun; 13(3):1499-1504. PubMed ID: 35837171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
    Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
    Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.
    Zhou T; Mahn R; Möhring C; Sadeghlar F; Meyer C; Toma M; Kreppel B; Essler M; Glowka T; Matthaei H; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
    Front Oncol; 2022; 12():933943. PubMed ID: 35957899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.
    Cheng Y; Zhang J; Qin SK; Hua HQ
    Onco Targets Ther; 2018; 11():5957-5962. PubMed ID: 30271179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report.
    Buchner D; Drebber U; Chang DH; Stippel DL
    J Med Case Rep; 2016 Oct; 10(1):299. PubMed ID: 27784337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.
    Tan JH; Zhou WY; Zhou L; Cao RC; Zhang GW
    Turk J Gastroenterol; 2020 Mar; 31(3):246-256. PubMed ID: 32343237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring
    Li X; Gao L; Qiu M; Cao D
    Onco Targets Ther; 2021; 14():2815-2819. PubMed ID: 33911878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent biliary dissemination of colon cancer liver metastasis: a case report.
    Onishi I; Kayahara M; Takei R; Makita N; Munemoto M; Yagi Y; Kawashima A
    J Med Case Rep; 2018 Oct; 12(1):314. PubMed ID: 30367665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
    Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study.
    Wong M; Kim J; George B; Eriksen C; Pearson T; Robbins J; Zimmerman MA; Hong JC
    J Surg Res; 2019 Oct; 242():23-30. PubMed ID: 31059945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways.
    Jiao CY; Feng QC; Li CX; Wang D; Han S; Zhang YD; Jiang WJ; Chang J; Wang X; Li XC
    Cell Death Dis; 2021 Jan; 12(1):63. PubMed ID: 33431813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection?
    Miyazaki M; Ito H; Nakagawa K; Ambiru S; Shimizu H; Shimizu Y; Kato A; Nakamura S; Omoto H; Nakajima N; Kimura F; Suwa T
    Surgery; 1998 Feb; 123(2):131-6. PubMed ID: 9481397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.
    Lunsford KE; Javle M; Heyne K; Shroff RT; Abdel-Wahab R; Gupta N; Mobley CM; Saharia A; Victor DW; Nguyen DT; Graviss EA; Kaseb AO; McFadden RS; Aloia TA; Conrad C; Li XC; Monsour HP; Gaber AO; Vauthey JN; Ghobrial RM;
    Lancet Gastroenterol Hepatol; 2018 May; 3(5):337-348. PubMed ID: 29548617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulomatous cholangitis mimicking hilar cholangiocarcinoma: a case report.
    Fujisaki S; Takashina M; Sakurai KI; Tomita R; Takayama T
    BMC Gastroenterol; 2020 Nov; 20(1):369. PubMed ID: 33148196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic
    Su YL; Ng CT; Jan YH; Hsieh YL; Wu CL; Tan KT
    Onco Targets Ther; 2021; 14():3895-3901. PubMed ID: 34234458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States.
    Mukkamalla SKR; Naseri HM; Kim BM; Katz SC; Armenio VA
    J Natl Compr Canc Netw; 2018 Apr; 16(4):370-376. PubMed ID: 29632056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.